TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11571096
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg oral methyltestosterone (meT) in combination with 0.625 mg oral esterified estrogen (E)
Study: 11571096
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg oral esterified estrogen (E) alone
Study: 15101020
Drug: Aspirin 162
Normalized name: aspirin 162 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 162 mg
Study: 9262254
Drug: Aspirin 40.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 40.5 mg
Study: 30557879
Drug: Short-term steroid
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term steroid regimen (prednisolone 0.8-1.0 mg/kg/day for 4-6 weeks, then 0.5-0.6 mg/kg/alternate day for 4 weeks)
Study: 30557879
Drug: Conventional steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional steroid administration (control group, n = 140)
Study: 22821285
Drug: Selenium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium intake (μg/day/1,000 kcal)
Study: 22821285
Drug: Calcium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium intake (mg/day/1,000 kcal)
Study: 21535123
Drug: Antenatal testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal testing initiation for medication-treated gestational diabetes
Study: 18692175
Drug: Tolvaptan (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan (15 mg, titratable to 30 or 60 mg) once daily for 30 days
Study: 12185505
Drug: Conventional chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy with CEOP-Bleo (cyclophosphamide 750 mg/m(2), vincristine 1.4 mg/m(2), prednisone 40 mg/m(2), epirubicin 70 mg/m(2), and bleomycin 10 mg/m(2)) every 21 days for six cycles followed by radiotherapy (35-45 Gy, mean 38 Gy)
Study: 12185505
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy with mega CEOP-Bleo (cyclophosphamide 1000 mg/m(2), epirubicin 120 mg/m(2), vincristine, prednisone, and bleomycin at the same doses) every 21 days for six cycles followed by radiotherapy (35-45 Gy, mean 38 Gy)
Study: 28749158
Drug: Trauma-focused cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma-focused cognitive behavioral therapy treatment (TF-CBT-anger)
Study: 24755139
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g RBEP (rice bran exo‐biopolymer)
Study: 24755139
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g placebo
Study: 21909060
Drug: Glucose solution
Normalized name: TrueControl Glucose Solution Level 0
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucose solution
Study: 19227650
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with natural rubber latex (NRL) for 3 years
Study: 12559481
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (N=9)
Study: 2167800
Drug: Oral frusemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral frusemide
Study: 7324942
Drug: 10-day treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day treatment with sulfafurazole
Study: 7324942
Drug: 42-day treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 42-day treatment
Study: 30679107
Drug: Four courses
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four courses of S-1 (80 mg/day per m2 for 4 weeks followed by 2 weeks rest)
Study: 30679107
Drug: Eight courses
Normalized name: OC Eight
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eight courses of S-1 (80 mg/day per m2 for 4 weeks followed by 2 weeks rest)
Study: 26858958
Drug: Peer support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer support intervention (additional to DMP), running over 24 months, including peer supporter recruitment, training, weekly physical exercise meetings, and monthly discussions on diabetes-related topics.
Study: 20873252
Drug: magnetotherapy, manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: magnetotherapy, manual massage and exercise therapy
Study: 15910951
Drug: Home visitation
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home visitation by nurses in addition to standard treatment
Study: 11876704
Drug: Bismuth-based triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth-based triple regimens (treatment group)
Study: 11876704
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (no treatment group)
Study: 10606847
Drug: Locobase(R) fatty
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locobase(R) fatty cream containing a mixture of 5% lactic acid and 20% propylene glycol (LPL)
Study: 10606847
Drug: Essex(R) (Diprobase(R))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essex(R) (Diprobase(R)) cream (LPE)
Study: 10606847
Drug: Locobase(R) fatty
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locobase(R) fatty cream containing 5% urea
Study: 10606847
Drug: Locobase(R) fatty
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locobase(R) fatty cream containing 20% propylene glycol
Study: 6085375
Drug: Nitrendipine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (2 X 10 to 2 X 20 mg/day)
Study: 6085375
Drug: Propranolol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (2 X 80 to 2 X 160 mg/day)
Study: 30473390
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of delayed start time and sleep education programme
Study: 30309835
Drug: Tailored, therapist-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored, therapist-guided internet-based cognitive behavioral therapy (ICBT)
Study: 23582138
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of fentanyl plus open-label boluses of fentanyl
Study: 23582138
Drug: Placebo (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (continuous infusion of placebo plus open-label boluses of fentanyl)
Study: 20872323
Drug: Traditional oral
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional oral feeding
Study: 18394499
Drug: Placebo (sham
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sham treatment with disconnected ultrasound and magnetotherapy equipment)
Study: 16451396
Drug: Flexible treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible treatment schedule
Study: 16451396
Drug: Fixed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed treatment schedule
Study: 8015881
Drug: Amoxicillin/clavulanate (iv
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate (iv 100 mg/kg/d, then oral 50 mg/kg/d after 48 hours afebrile)
Study: 8015881
Drug: Benzylpenicillin (100,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzylpenicillin (100,000 IU/kg/d) + netilmicin (5 mg/kg/d) + metronidazole (30 mg/kg/d) (iv, then oral metronidazole 30 mg/kg/d)
Study: 3323609
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid infusion with somatostatin and hormone replacement (insulin/glucagon/growth hormone)
Study: 3323609
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid infusion alone
Study: 29761861
Drug: ICD plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD plus medical therapy
Study: 25178073
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of nebivolol and amlodipine (n=62)
Study: 25178073
Drug: Free combination
Normalized name: SUNSCREEN-29 PABA-FREE COMBINATION LOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free combination of nebivolol and amlodipine (n=62)
Study: 22863282
Drug: Scheduled intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheduled intravenous analgesia (nurse-administered hydromorphone)
Study: 14532151
Drug: Rituximab (anti-CD20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (anti-CD20 chimeric monoclonal antibody)
Study: 8673528
Drug: Didanosine 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine 500 mg/d
Study: 8673528
Drug: Didanosine 200
Normalized name: didanosine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine 200 mg/d
Study: 8673528
Drug: Zidovudine 600
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine 600 mg/d
Study: 1499856
Drug: Intravenous portal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous portal insulin infusion (IPII) via the umbilical vein for 4 months
Study: 1499856
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous insulin infusion (CSII) for 4 months
Study: 6540532
Drug: Moderate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate dose prednisolone (60 mg/m2/day p.o. for 21 days)
Study: 21683660
Drug: Blue light
Normalized name: Ocuvite Blue Light Mini Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blue light therapy (400 lux for 30 minutes per day, Monday through Friday, for 4 weeks)
Study: 21683660
Drug: Placebo red
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo red light therapy (75 lux)
Study: 21683660
Drug: Placebo red
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo red light therapy
Study: 19357997
Drug: 0.5% lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5% lidocaine with 0.1 mg.kg(‐1) morphine (Group LM)
Study: 19357997
Drug: 0.5% lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5% lidocaine with 1.5 mg.kg(‐1) tramadol (Group LT)
Study: 19357997
Drug: 0.5% lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5% lidocaine (Group L)
Study: 17453361
Drug: No adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjuvant endocrine therapy
Study: 12205826
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (nonfunctioning hearing aid)
Study: 30540649
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron polysaccharide 150 mg twice daily for 16 weeks
Study: 29210011
Drug: Um‐PEA 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Um‐PEA 600 mg twice daily
Study: 26008654
Drug: Oral tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tramadol 100 mg (Group-T, n=30)
Study: 26008654
Drug: Famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 40 mg (Group-F, n=30)
Study: 17852302
Drug: Multidisciplinary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary treatment (including psychological/cognitive-behavioral components)
Study: 17852302
Drug: Not applicable
Normalized name: AIR 1000 mL in 1 L NOT APPLICABLE GAS
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not applicable (control group of patients who did not start treatment)
Study: 10929741
Drug: i.v. heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. heparin (5,000 IU bolus + 1,000 IU/h)
Study: 30861061
Drug: ZTI-01 (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZTI-01 (6 g q8h for 7 days)
Study: 30861061
Drug: Piperacillin-tazobactam (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin-tazobactam (4.5 g IV q8h for 7 days)
Study: 27773347
Drug: Chewed ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chewed ticagrelor tablets
Study: 27773347
Drug: Crushed ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Crushed ticagrelor tablets
Study: 27773347
Drug: Integral ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integral ticagrelor tablets
Study: 26373270
Drug: HMB-FA (free
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMB-FA (free acid form) administered in capsules
Study: 26373270
Drug: HMB-FA (free
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMB-FA (free acid form) administered in water
Study: 26373270
Drug: Ca-HMB (calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ca-HMB (calcium salt form) administered in capsules
Study: 26373270
Drug: Ca-HMB (calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ca-HMB (calcium salt form) administered in water
Study: 24530134
Drug: Conventional group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional group (daily steroids)
Study: 24530134
Drug: Pulse group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse group (weekly doses of steroids)
Study: 9444412
Drug: Oral fleroxacin
Normalized name: fleroxacin
DrugBank: Fleroxacin (DB04576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fleroxacin 400 mg once a day for 7 days
Study: 9444412
Drug: Cefalexin 500
Normalized name: Cefalexin 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefalexin 500 mg three times daily for 7 days
Study: 2146967
Drug: Caffeine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (75 mg tablets)
Study: 31792921
Drug: Givosiran 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Givosiran 2.5 mg/kg, administered subcutaneously monthly
Study: 21477846
Drug: Tinzaparin 175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinzaparin 175 IU/kg once daily
Study: 28029329
Drug: Dose-adjusted warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-adjusted warfarin for 6 months
Study: 15832067
Drug: Self-hypnosis (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-hypnosis (mean of 2.4 sessions, SD 1.7; range 2-5 sessions) along with standard anti-allergic pharmacological treatment
Study: 11981150
Drug: Intravenous clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous clonidine (group C)
Study: 7621059
Drug: High-dose continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose continuous nebulization of albuterol (7.5 mg/h)
Study: 7621059
Drug: High-dose intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intermittent nebulization of albuterol (2.5 mg every 20 minutes for four hours)
Study: 28096
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg clobazam
Study: 7937568
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg clobazam
Study: 26727655
Drug: Tocilizumab IV
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab IV 8 mg/kg every 4 weeks over 31 min
Study: 26727655
Drug: Standard 60-min
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 60-min infusions of Tocilizumab IV 8 mg/kg every 4 weeks
Study: 15612979
Drug: SRL-ST (sirolimus-steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRL-ST (sirolimus-steroid regimen without cyclosporine)
Study: 15612979
Drug: SRL-CsA-ST (sirolimus-cyclosporine-steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRL-CsA-ST (sirolimus-cyclosporine-steroid regimen)
Study: 12211647
Drug: Vitamin supplementation
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin supplementation (folic acid 5 mg, pyridoxine 40 mg, cyanocobalamin 1 mg once daily)
Study: 7595106
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment including manipulation
Study: 98802
Drug: Cigarettes delivering
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cigarettes delivering 0.2 mg nicotine/cigarette
Study: 98802
Drug: Cigarettes delivering
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cigarettes delivering 2.0 mg nicotine/cigarette
Study: 31162549
Drug: Hydrochlorothiazide (HCT)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCT) 12.5 mg
Study: 21795443
Drug: BOLUS (25-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: BOLUS (25-g dose of whey protein)
Study: 21795443
Drug: PULSE (ten
Approvals — FDA: no, EMA: no, PMDA: no
Description: PULSE (ten 2.5-g drinks every 20 min of whey protein)
Study: 12760903
Drug: Duodenal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Duodenal infusion of 0.1 N hydrochloric acid
Study: 11115818
Drug: Duodenal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Duodenal infusion of saline
Study: 3536377
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg methadone
Study: 8498759
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg methadone (placebo)
Study: 3561160
Drug: Metoclopramide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (10 mg, iv.)
Study: 21235477
Drug: Subcutaneous immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunotherapy (SCIT) with D. pteronyssinus extract
Study: 18155056
Drug: Preemptive epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive epidural analgesia (2 mg morphine in 15 mL of 1% lidocaine)
Study: 18155056
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (normal saline in 15 mL)
Study: 16564436
Drug: Imaginal reliving
Normalized name: LidoPro Pain Relieving Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imaginal reliving in cognitive therapy for PTSD
Study: 11197521
Drug: Various treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatments completed by women
Study: 11197521
Drug: Limitations in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Limitations in daily occupations
Study: 11197521
Drug: Pain variables,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain variables, daily occupations, sick-leave, work variables
Study: 9088300
Drug: Labored breathing
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labored breathing for twice 30 min (with a 30‐min interval in between)
Study: 8392957
Drug: Ribavirin (0.8-1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin (0.8-1.0 g daily)
Study: 8392957
Drug: Interferon beta
Normalized name: Interferon beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon beta (3 MU three times weekly)
Study: 8392957
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ribavirin and interferon beta
Study: 27198539
Drug: Contralateral natural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contralateral natural antagonists (control teeth)
Study: 24469600
Drug: Amisulpride (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride (50 mg) with Korean traditional food
Study: 24469600
Drug: Amisulpride (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride (50 mg) under fasting state
Study: 22241786
Drug: Oral clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clarithromycin 500 mg/bid for 2 weeks and then 250 mg/d for 6 weeks
Study: 22241786
Drug: Topical mometasone
Normalized name: mometasone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical mometasone furoate 200 mcg/d for 8 weeks added to clarithromycin regimen
Study: 3653498
Drug: Nicardipine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (30 mg three times a day)
Study: 22399275
Drug: 0.8 g
Normalized name: Alcohol 0.8 g in 1 mL TOPICAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 g CMC-001
Study: 22399275
Drug: 0.4 g
Normalized name: psyllium 0.4 GM Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 g CMC-001
Study: 22399275
Drug: 0.2 g
Normalized name: methionine 0.2 gram ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 g CMC-001
Study: 30184133
Drug: Scopolamine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (4 μg/kg)
Study: 11475269
Drug: Repaglinide 0.5
Normalized name: repaglinide 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide 0.5 mg
Study: 12520624
Drug: Repaglinide 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide 1.0 mg
Study: 12520624
Drug: Repaglinide 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide 2.0 mg
Study: 25863562
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral vitamin D3 (four doses of 2.5 mg at weeks 0, 2, 4, and 6)
Study: 25863562
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral vitamin D3
Study: 25863562
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral vitamin D3 and Placebo
Study: 24618443
Drug: Oral pancreatic
Normalized name: pancreatin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pancreatic enzyme supplementation
Study: 9585778
Drug: Dopamine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine 2.5 mcg/kg beginning 1 hour before arteriography and continuing for 12 hours
Study: 11534531
Drug: β-blockade therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-blockade therapy
Study: 514499
Drug: Amipaque 280
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amipaque 280 mg I/ml
Study: 662085
Drug: Isopaque Cerebral
Normalized name: Sus scrofa cerebral cortex preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isopaque Cerebral 280 mg I/ml
Study: 662085
Drug: Amipaque 280
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amipaque 280 mg I/ml (selective external carotid injection)
Study: 662085
Drug: Isopaque (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isopaque (selective external carotid injection)